1 results match your criteria: "France. Center of Clinical Investigations in Biotherapies of Cancer 1428[Affiliation]"
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
Science
November 2015
Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, France. INSERM U1015, GRCC, Villejuif, France. University of Paris Sud XI, Kremlin-Bicêtre, France. Center of Clinical Investigations in Biotherapies of Cancer 1428, Villejuif, France.
Article Synopsis
- Antibodies targeting CTLA-4 have shown effectiveness as cancer immunotherapy, with findings indicating that their antitumor effects are influenced by specific Bacteroides species.
- Research in both mice and patients revealed that a T cell response to B. thetaiotaomicron or B. fragilis is linked to the effectiveness of CTLA-4 blockade therapies.
- In studies, antibiotic treatment or the absence of gut bacteria eliminated the tumor response to CTLA-4 blockade, but this was restored through methods such as administering B. fragilis, immunization with its polysaccharides, or transferring specific T cells.